NEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO). Investors who purchased Novo Nordisk securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVO.
Investigation Details
On June 23, 2025, Novo Nordisk announced that it would end its partnership with Hims & Hers Health, Inc. ("Hims") to distribute its weight loss drug Wegovy, claiming that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization' and are disseminating deceptive marketing that put patient safety at risk." Following this news, Novo Nordisk stock dropped 5.5% on the same day.
What's Next?
If you are aware of any facts relating to this investigation or purchased Novo Nordisk securities, you can assist this investigation by visiting the firm's site: bgandg.com/NVO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on ACCESS Newswire
